Efficacy, Safety, and Tolerability of a Halobetasol 0.01% Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. J of Skin 2019, 3, S29. https://doi.org/10.25251/skin.3.supp.29.